These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 32039372)

  • 1. The role of the gut microbiome in chronic liver disease: the clinical evidence revised.
    Schwenger KJ; Clermont-Dejean N; Allard JP
    JHEP Rep; 2019 Sep; 1(3):214-226. PubMed ID: 32039372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
    Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
    Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
    Cho MS; Kim SY; Suk KT; Kim BY
    J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Physiological patterns of intestinal microbiota. The role of dysbacteriosis in obesity, insulin resistance, diabetes and metabolic syndrome].
    Halmos T; Suba I
    Orv Hetil; 2016 Jan; 157(1):13-22. PubMed ID: 26708682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease and obesity: the role of the gut bacteria.
    Schwenger KJP; Bolzon CM; Li C; Allard JP
    Eur J Nutr; 2019 Aug; 58(5):1771-1784. PubMed ID: 30306296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probiotics, prebiotics, synbiotics and insulin sensitivity.
    Kim YA; Keogh JB; Clifton PM
    Nutr Res Rev; 2018 Jun; 31(1):35-51. PubMed ID: 29037268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy.
    Cammarota G; Ianiro G; Cianci R; Bibbò S; Gasbarrini A; Currò D
    Pharmacol Ther; 2015 May; 149():191-212. PubMed ID: 25561343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?
    Li DY; Yang M; Edwards S; Ye SQ
    JPEN J Parenter Enteral Nutr; 2013 Nov; 37(6):787-93. PubMed ID: 23538296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies.
    West CE; Renz H; Jenmalm MC; Kozyrskyj AL; Allen KJ; Vuillermin P; Prescott SL;
    J Allergy Clin Immunol; 2015 Jan; 135(1):3-13; quiz 14. PubMed ID: 25567038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the microbiome for human health: from basic science to clinical applications.
    Mohajeri MH; Brummer RJM; Rastall RA; Weersma RK; Harmsen HJM; Faas M; Eggersdorfer M
    Eur J Nutr; 2018 May; 57(Suppl 1):1-14. PubMed ID: 29748817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex.
    Rizzetto L; Fava F; Tuohy KM; Selmi C
    J Autoimmun; 2018 Aug; 92():12-34. PubMed ID: 29861127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation].
    Aitbaev KA; Murkamilov IT; Fomin VV
    Ter Arkh; 2017; 89(8):120-128. PubMed ID: 28914862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting gut microbiota as a possible therapy for diabetes.
    He C; Shan Y; Song W
    Nutr Res; 2015 May; 35(5):361-7. PubMed ID: 25818484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives.
    Malaguarnera G; Giordano M; Nunnari G; Bertino G; Malaguarnera M
    World J Gastroenterol; 2014 Nov; 20(44):16639-48. PubMed ID: 25469033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut microbiota alterations and dietary modulation in childhood malnutrition - The role of short chain fatty acids.
    Pekmez CT; Dragsted LO; Brahe LK
    Clin Nutr; 2019 Apr; 38(2):615-630. PubMed ID: 29496274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.
    Felizardo RJF; Watanabe IKM; Dardi P; Rossoni LV; Câmara NOS
    Pharmacol Res; 2019 Mar; 141():366-377. PubMed ID: 30639376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease.
    Mafra D; Lobo JC; Barros AF; Koppe L; Vaziri ND; Fouque D
    Future Microbiol; 2014; 9(3):399-410. PubMed ID: 24762311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.